SPDL1 and non-small cell lung carcinoma: Costantini et al. investigated the prognostic role of sPD-L1 in the context of immunotherapy and found that high sPD-L1 expression correlated with shorter overall survival in a cohort of 43 NSCLC patients treated with nivolumab [19].